Literature DB >> 11888887

Cellular localization and function of Fas ligand (CD95L) in tumors.

Masayuki Kurooka1, Gerard J Nuovo, Michael A Caligiuri, Gary J Nabel.   

Abstract

The localization of CD95L in different cell types within tumors has not been well defined, and its role in tumor growth is uncertain. In this study, CD95L expression and its contribution to tumor growth are evaluated using genetic polymorphisms and adoptive transfer in genetically deficient mice. CD95L was detected in tumors in vivo at levels up to 10(4)-fold higher than those in cell culture and predominantly in host tumor-infiltrating macrophages, but not in tumor cells. Adoptive transfer into genetically deficient mice revealed that host CD95-CD95L function did not alter tumor growth, demonstrating that CD95L alone does not affect tumor growth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888887

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-02-17       Impact factor: 3.905

Review 2.  Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Authors:  Vesna Risso; Elodie Lafont; Matthieu Le Gallo
Journal:  Cell Death Dis       Date:  2022-03-17       Impact factor: 9.685

3.  Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.

Authors:  Mohammad Hashemi; Aliakbar Fazaeli; Saeid Ghavami; Ebrahim Eskandari-Nasab; Farshid Arbabi; Mohammad Ali Mashhadi; Mohsen Taheri; Wiem Chaabane; Mayur V Jain; Marek J Łos
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

4.  Quantitative assessment of the association between Fas/FasL gene polymorphism and susceptibility to esophageal carcinoma in a north Chinese population.

Authors:  Meijuan Zhang; Cuiping Wu; Baohuan Li; Wenjun Du; Chuanzhen Zhang; Ziping Chen
Journal:  Cancer Med       Date:  2016-01-27       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.